![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif)
tamoxifen citrate![Patient Information Patient Information](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/btn-patient-info.gif) The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | Novaldex tamoxifen Tamoxifeni Citras | | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | Nolvadex | | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | Foreign brand names: | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | Apo-Tamox Clonoxifen Dignotamoxi Ebefen Emblon Estroxyn Fentamox Genox Gen-Tamoxifen Jenoxifen Kessar Ledertam Lesporene Nolgen Noltam Nolvadex-D Nourytam Novofen Novo-Tamoxifen Oestrifen Oncotam PMS-Tamoxifen Soltamox Tamax Tamaxin Tamifen Tamizam Tamofen Tamoxasta Zemide | | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | Abbreviations: | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | TAM TMX | | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | ICI 46,474 | | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure names: | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) | - (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)
- 1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
| | ![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509200123im_/http://www.cancer.gov/images/spacer.gif) |